BRPI0410702A - polinucleotìdeo isolado, composição, métodos para preparar um vìrus de influenza e um veìculo de liberação de genes, e para imunizar um indivìduo contra um patógeno, vìrus, célula, e, vetor - Google Patents

polinucleotìdeo isolado, composição, métodos para preparar um vìrus de influenza e um veìculo de liberação de genes, e para imunizar um indivìduo contra um patógeno, vìrus, célula, e, vetor

Info

Publication number
BRPI0410702A
BRPI0410702A BRPI0410702-0A BRPI0410702A BRPI0410702A BR PI0410702 A BRPI0410702 A BR PI0410702A BR PI0410702 A BRPI0410702 A BR PI0410702A BR PI0410702 A BRPI0410702 A BR PI0410702A
Authority
BR
Brazil
Prior art keywords
virus
composition
pathogen
vector
cell
Prior art date
Application number
BRPI0410702-0A
Other languages
English (en)
Inventor
Yoshihiro Kawaoka
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Publication of BRPI0410702A publication Critical patent/BRPI0410702A/pt
Publication of BRPI0410702B1 publication Critical patent/BRPI0410702B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"POLINUCLEOTìDEO ISOLADO, COMPOSIçãO, MéTODOS PARA PREPARAR UM VìRUS DE INFLUENZA E UM VEìCULO DE LIBERAçãO DE GENES, E PARA IMUNIZAR UM INDIVìDUO CONTRA UM PATóGENO, VìRUS, CéLULA, E, VETOR". A invenção provê uma composição utilizável para preparar vírus de influenza de titulo elevado, por exemplo na ausência de vírus auxiliar, que inclui uma seqüência de um isolado de vírus de influenza de título elevado.
BRPI0410702-0A 2003-05-28 2004-05-27 Composição, métodos para preparar um vírus de influenza e um veículo de liberação de genes, e, vírus BRPI0410702B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47379803P 2003-05-28 2003-05-28
US60/473,798 2003-05-28
PCT/US2004/016680 WO2004112831A2 (en) 2003-05-28 2004-05-27 High titer recombinant influenza viruses for vaccines and gene therapy

Publications (2)

Publication Number Publication Date
BRPI0410702A true BRPI0410702A (pt) 2006-06-13
BRPI0410702B1 BRPI0410702B1 (pt) 2022-04-12

Family

ID=33539054

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410702-0A BRPI0410702B1 (pt) 2003-05-28 2004-05-27 Composição, métodos para preparar um vírus de influenza e um veículo de liberação de genes, e, vírus

Country Status (18)

Country Link
US (1) US8475806B2 (pt)
EP (1) EP1631663B1 (pt)
JP (2) JP5215561B2 (pt)
KR (1) KR100908757B1 (pt)
CN (1) CN1826407B (pt)
AU (1) AU2004249133B2 (pt)
BR (1) BRPI0410702B1 (pt)
CA (1) CA2525953C (pt)
EA (1) EA012965B1 (pt)
ES (1) ES2593082T3 (pt)
HU (1) HUE030962T2 (pt)
IL (2) IL171831A (pt)
MX (1) MX342639B (pt)
NO (1) NO341506B1 (pt)
NZ (1) NZ543446A (pt)
UA (1) UA92132C2 (pt)
WO (1) WO2004112831A2 (pt)
ZA (1) ZA200510309B (pt)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8715940B2 (en) 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
ES2217967B1 (es) * 2003-03-31 2006-01-01 Consejo Sup. Investig. Cientificas Procedimiento de produccion de particulas virales vacias (vlps) del virus inductor de la bursitis infecciosa (ibdv), composiciones necesarias para su puesta a punto y su uso en la elaboracion de vacunas frente al ibdv.
CA2525953C (en) 2003-05-28 2023-10-10 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines and gene therapy
ES2307345B1 (es) * 2004-01-21 2009-11-13 Consejo Sup. Investig. Cientificas Capsidas vacias quimericas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones.
ES2307346B1 (es) * 2004-01-21 2009-11-13 Consejo Sup. Investig. Cientificas Capsidas vacias (vlps(-vp4)) del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones.
EA200701097A1 (ru) 2004-11-19 2007-10-26 Висконсин Эламни Рисёч Фаундэйшн Рекомбинантные векторы вируса гриппа с тандемными транскрипционными единицами
US7572620B2 (en) 2005-01-11 2009-08-11 Wisconsin Alumni Research Foundation H3 equine influenza A virus
US7790434B2 (en) 2005-06-21 2010-09-07 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
EP1917352A4 (en) * 2005-06-21 2009-03-25 Medimmune Vaccines Inc METHODS AND COMPOSITIONS FOR EXPRESSING HETEROLOGOUS PROTEASE
ES2310062B1 (es) * 2005-07-15 2009-11-13 Bionostra, S.L. Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones.
US7871626B2 (en) 2005-08-04 2011-01-18 St. Jude Children's Research Hospital Modified influenza virus for monitoring and improving vaccine efficiency
ES2525518T3 (es) 2005-11-01 2014-12-26 Novartis Vaccines And Diagnostics Gmbh Vacunas virales derivadas de células con niveles reducidos de ADN celular residual
KR101484305B1 (ko) * 2006-03-10 2015-01-19 위스콘신 얼럼나이 리서어치 화운데이션 Ｈ3 말 인플루엔자 ａ 바이러스
JP2007259758A (ja) * 2006-03-28 2007-10-11 Wisconsin Alumni Research Foundation Ｈ３型ウマａ型インフルエンザウイルス
CA2647985C (en) * 2006-03-31 2014-12-30 Warf-Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
DK2016194T3 (en) * 2006-04-19 2015-06-15 Medimmune Llc METHODS AND COMPOSITIONS FOR EXPRESSION OF VIRAL NEGATIVE SENSE RNA IN DOG CELLS
AU2013204811B2 (en) * 2006-04-19 2015-01-22 Medimmune, Llc Methods and compositions for expressing negative-sense viral rna in canine cells
WO2007146057A2 (en) * 2006-06-09 2007-12-21 Wisconsin Alumni Research Foundation Screening method for modulators of viral transcription or replication
AU2007297801A1 (en) 2006-07-14 2008-03-27 Sanofi Pasteur Biologics Co. Construction of recombinant virus vaccines by direct transposon-mediated insertion of foreign immunologic determinants into vector virus proteins
EP2069483A4 (en) * 2006-09-29 2010-10-27 Sanofi Pasteur Biologics Co RECOMBINANT RHINOVIRAL VECTORS
US20100190842A1 (en) * 2007-04-12 2010-07-29 Alnylam Pharmaceuticals, Inc. Influenza polynucleotides, expression constructs, compositions, and methods of use
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
EP2493912B1 (en) * 2009-10-26 2020-07-29 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in vero cells
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
WO2012006561A2 (en) * 2010-07-08 2012-01-12 New York Medical College Influenza virus detection and diagnosis
KR102080061B1 (ko) * 2011-06-24 2020-02-21 플루젠, 인코퍼레이티드 인플루엔자 바이러스 돌연변이체들 및 그들의 용도들
JP2014527799A (ja) 2011-08-26 2014-10-23 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション 変異型ｐｂ２遺伝子セグメントを有する弱毒化生ワクチンとしてのインフルエンザウイルス
CN103608453B (zh) * 2012-03-02 2018-07-24 思齐乐 流感病毒重配
JP2013099339A (ja) * 2013-01-04 2013-05-23 Wisconsin Alumni Research Foundation Ｈ３型ウマａ型インフルエンザウイルス
WO2015009743A1 (en) 2013-07-15 2015-01-22 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in mdck or vero cells or eggs
KR101493613B1 (ko) * 2013-10-25 2015-02-13 위스콘신 얼럼나이 리서어치 화운데이션 Ｈ3 말 인플루엔자 ａ 바이러스
WO2015142671A2 (en) 2014-03-17 2015-09-24 Flugen, Inc. Influenza virus vectors and uses therefor
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
US10927151B2 (en) 2015-06-09 2021-02-23 Sanofi Pasteur Inc. Methods of optimizing nucleotide sequences encoding engineered influenza proteins
US9890363B2 (en) 2015-07-06 2018-02-13 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
US10912864B2 (en) 2015-07-24 2021-02-09 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
JP6560056B2 (ja) * 2015-08-07 2019-08-14 ウィスコンシン アルムニ リサーチ ファンデイション Ｈ３型ウマａ型インフルエンザウイルス
RU2660562C2 (ru) * 2016-03-30 2018-07-06 Общество с ограниченной ответственностью "ФАРМИНТЕРПРАЙСЕЗ БИОТЕХ" Аттенуированный гриппозный вектор и мукозальная универсальная гриппозная вакцина на его основе
US11197925B2 (en) 2016-02-19 2021-12-14 Wisconsin Alumni Research Foundation (Warf) Influenza B virus replication for vaccine development
JP2017038622A (ja) * 2016-11-21 2017-02-23 ウィスコンシン アルムニ リサーチ ファンデイション Ｈ３型ウマａ型インフルエンザウイルス
WO2019084310A1 (en) 2017-10-25 2019-05-02 Yoshihiro Kawaoka HAS RECOMBINANT INFLUENZA VIRUSES STABILIZED FOR EGG REPLICATION
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
JP2018088928A (ja) * 2018-02-13 2018-06-14 ウィスコンシン アルムニ リサーチ ファンデイション Ｈ３型ウマａ型インフルエンザウイルス
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
JP7655849B2 (ja) 2018-08-20 2025-04-02 ウィスコンシン アルムニ リサーチ ファンデイション ヘマグルチニン（ｈａ）タンパク質内の非ドミナントエピトープに対する免疫応答を誘起するためのベクター
EP3914295A2 (en) 2019-01-23 2021-12-01 Yoshihiro Kawaoka Mutations that confer genetic stability to additional genes in influenza viruses
EP3921413A1 (en) 2019-02-08 2021-12-15 Wisconsin Alumni Research Foundation (WARF) Humanized cell line
CN114929269A (zh) 2019-05-01 2022-08-19 威斯康星校友研究基金会(Warf) 用于疫苗开发的改进的流感病毒复制
US11807872B2 (en) 2019-08-27 2023-11-07 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
JP2023511444A (ja) 2020-01-24 2023-03-17 ウィスコンシン アルムニ リサーチ ファンデイション 安定化されたｎａを有する組換えインフルエンザウイルス
WO2021195410A1 (en) 2020-03-25 2021-09-30 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses
EP4185601A4 (en) 2020-07-21 2024-10-30 Flugen, Inc. SKELETON OF THE INFLUENZA VIRUS
CN118497151B (zh) * 2024-07-11 2024-10-01 昆明理工大学 表达trail的重组溶瘤流感病毒及应用
WO2026076074A1 (en) 2024-10-02 2026-04-09 Stamford Pharmaceuticals Inc. Functionalized viruses and related compositions and methods

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4071618A (en) 1974-09-03 1978-01-31 Research Foundation For Microbial Diseases Of Osaka University Process for preparing virus disease live vaccines
JPS57136528A (en) 1981-02-09 1982-08-23 Hayashibara Biochem Lab Inc Preparation of viral vaccine
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US5840520A (en) 1989-08-28 1998-11-24 Aviron Recombinant negative strand RNA virus expression systems
US5854037A (en) 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
ATE257175T1 (de) 1994-07-18 2004-01-15 Conzelmann Karl Klaus Prof Dr Rekombinantes infektiöses nicht-in-segmente- geteiltes, negativ-strange-rns-virus
US5789229A (en) 1994-09-30 1998-08-04 Uab Research Foundation Stranded RNA virus particles
US5716821A (en) 1994-09-30 1998-02-10 Uab Research Foundation Prevention and treatment of respiratory tract disease
WO1998002530A1 (en) 1996-07-15 1998-01-22 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
BR9809456B1 (pt) 1997-05-23 2011-06-28 molécula isolada de polinucleotìdeo, composição de célula ou isenta de célula, partìcula de piv infeciosa, atenuada e imunogênica, e, composição imunogênica.
KR100281676B1 (ko) * 1997-11-29 2001-04-02 신동권 신규한독감생백신바이러스
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
DE122008000035I1 (de) * 1999-04-06 2009-05-20 Wisconsin Alumni Res Found Rekombinante influenzaviren zur vakzinherstellung und gentherapie
US8715940B2 (en) 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
JP4927290B2 (ja) 2000-04-14 2012-05-09 ウィスコンシン アルムニ リサーチ ファンデイション 変異イオンチャンネルタンパク質を含んで成るウイルス
ES2319864T3 (es) * 2000-04-28 2009-05-14 St. Jude Children's Research Hospital Sistema de transfeccion de adn para la generacion de virus infecciosos de arn de cadena negativa.
EP1201760A1 (en) * 2000-10-30 2002-05-02 ARTEMIS Pharmaceuticals GmbH Influenza virus vector for human dendritic cells
KR101113432B1 (ko) 2002-02-13 2012-02-29 위스콘신 얼럼나이 리서어치 화운데이션 인플루엔자 바이러스 벡터의 패키징을 위한 신호
AU2004232992A1 (en) 2003-04-23 2004-11-04 Wisconsin Alumni Research Foundation Recombinant influenza viruses holding a mutation in a transmembrane protein gene
CA2525953C (en) 2003-05-28 2023-10-10 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines and gene therapy
WO2005028658A2 (en) 2003-05-28 2005-03-31 Wisconsin Alumni Research Foundation Recombinant influenza vectors with a polii promoter and ribozymes
EA200701097A1 (ru) 2004-11-19 2007-10-26 Висконсин Эламни Рисёч Фаундэйшн Рекомбинантные векторы вируса гриппа с тандемными транскрипционными единицами
CA2647985C (en) * 2006-03-31 2014-12-30 Warf-Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines

Also Published As

Publication number Publication date
KR100908757B1 (ko) 2009-07-22
AU2004249133B2 (en) 2009-05-28
JP2013059346A (ja) 2013-04-04
EP1631663B1 (en) 2016-08-24
EA200501890A1 (ru) 2006-06-30
JP2007518395A (ja) 2007-07-12
NO20056074L (no) 2006-03-22
US20050003349A1 (en) 2005-01-06
AU2004249133A1 (en) 2004-12-29
EA012965B1 (ru) 2010-02-26
US8475806B2 (en) 2013-07-02
EP1631663A2 (en) 2006-03-08
CA2525953A1 (en) 2004-12-29
CN1826407A (zh) 2006-08-30
ZA200510309B (en) 2006-08-30
CN1826407B (zh) 2013-09-11
WO2004112831A2 (en) 2004-12-29
NZ543446A (en) 2008-06-30
WO2004112831A3 (en) 2005-03-24
IL238584A0 (en) 2015-06-30
KR20060016095A (ko) 2006-02-21
CA2525953C (en) 2023-10-10
JP5215561B2 (ja) 2013-06-19
HUE030962T2 (en) 2017-06-28
IL238584B (en) 2020-06-30
BRPI0410702B1 (pt) 2022-04-12
JP5695020B2 (ja) 2015-04-01
ES2593082T3 (es) 2016-12-05
HK1082769A1 (zh) 2006-06-16
UA92132C2 (ru) 2010-10-11
IL171831A (en) 2015-05-31
MX342639B (es) 2016-10-07
NO341506B1 (no) 2017-11-27

Similar Documents

Publication Publication Date Title
BRPI0410702A (pt) polinucleotìdeo isolado, composição, métodos para preparar um vìrus de influenza e um veìculo de liberação de genes, e para imunizar um indivìduo contra um patógeno, vìrus, célula, e, vetor
BR0009580A (pt) Composição, processos para preparar vìrus da influenza, para preparar um veìculo de liberação de genes, para preparar vìrus da influenza defeituosos de replicação infecciosa, para imunizar um paciente contra um patógeno, para preparar vìrus infeccioso, e para preparar vìrus, vìrus, célula, vetor, célula hospedeira, e, uso do vìrus
EP3294326B1 (en) Prime-boost regimens involving administration of at least one mrna construct
WO2008068631A8 (en) Vaccines including antigen from four strains of influenza virus
SV2007002202A (es) Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones y tratamientos que los usan ref. pc32310a
HRP20220924T1 (hr) Imunoterapija zasnovana na pd-l1
WO2007126810A3 (en) High titer recombinant influenza viruses for vaccines
CY1118492T1 (el) Φαρμακοτεχνικες μορφες εμβολιου norovirus
CY1111378T1 (el) Προερχομενα απο κυτταρα ιικα εμβολια με χαμηλα επιπεδα υπολειμματικου κυτταρικου dna
CY1114643T1 (el) Νεοπλασματικες κυτταρικες σειρες nm-f9 (dsm acc2606) και nm-d4 (dsm acc2605), χρησεις αυτων
EP1594536A4 (en) ADJUVANT INFLUENZA VACCINE
MY160201A (en) Immunostimulatory oligonucleotides
WO2009026465A3 (en) Composition and methods of making and using influenza proteins
PE20200933A1 (es) Composiciones inmunoestimulantes
BRPI0920622A8 (pt) vacina contra o vírus da doença equina africana
PH12017501257A1 (en) Foot-and-mouth disease vaccine
WO2023064612A3 (en) Pharmaceutical compositions for delivery of viral antigens and related methods
Saxena et al. A sindbis virus replicon-based DNA vaccine encoding the rabies virus glycoprotein elicits immune responses and complete protection in mice from lethal challenge
MX2025008754A (es) Composiciones farmaceuticas para la administracion de antigenos de glicoproteina c, glicoproteina d y glicoproteina e del virus del herpes simple y metodos relacionados
BR0112486A (pt) Poliproteìna, molécula de ácido nucleico, plasmìdeo, vacina recombinante ou vacina atenuada, composição farmacêutica, e, método para imunizar um indivìduo contra hiv
AR031599A1 (es) Vacunas para el virus herpes equino tipo 1: virus que hospeda mutaciones dentro del gen inmediato precoz
AR034771A1 (es) Formulacion vacunal potenciada por la combinacion de un adn con un antigeno
BRPI0318114B8 (pt) Vacinação ou imunização utilizando um regime de iniciação-reforço
PE20212213A1 (es) Cepas de vbi y usos de las mismas
CY1116497T1 (el) Λειτουργικα ιομορφα σωματιδια γριπης (vlps)

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25I Requirement for requested change of headquarter

Owner name: WISCONSIN ALUMNI RESEARCH FOUNDATION (US)

Free format text: A FIM DE ATENDER A ALTERACAO DE ENDERECO REQUERIDA ATRAVES DA PETICAO NO 870180056720 DE 29/06/2018, E NECESSARIO ESCLARECER A DIVERGENCIA ENTRE O NOME DA EMPRESA TITULAR DO PEDIDO EO NOME DA EMPRESA QUE TEVE SEU ENDERECO ALTERADO.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B25H Request for change of headquarter rejected

Owner name: WISCONSIN ALUMNI RESEARCH FOUNDATION (US)

Free format text: INDEFERIDO O PEDIDO DE ALTERACAO DE SEDE CONTIDO NA PETICAO 870180056720 DE 29/06/2018, POR AUSENCIA DE CUMPRIMENTO DA EXIGENCIA PUBLICADA NA RPI NO 2488, DE 11/09/2018.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/05/2004, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2829 DE 25/03/2025 POR TER SIDO INDEVIDA.